[HTML][HTML] Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
M Orth, P Metzger, S Gerum, J Mayerle, G Schneider… - Radiation …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
[HTML][HTML] Drug resistance in pancreatic cancer: Impact of altered energy metabolism
C Grasso, G Jansen, E Giovannetti - Critical reviews in oncology …, 2017 - Elsevier
Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and
conventional treatments have little impact on survival. Therapeutically, this tumor is poorly …
conventional treatments have little impact on survival. Therapeutically, this tumor is poorly …
Targeting tumor-associated macrophages for cancer immunotherapy
Y Shu, P Cheng - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2020 - Elsevier
Macrophages are important effector cells of the innate immune system and are also major
components of the tumor microenvironment (TME). Macrophages that are abundant in the …
components of the tumor microenvironment (TME). Macrophages that are abundant in the …
[HTML][HTML] GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
C Pecoraro, B Faggion, B Balboni, D Carbone… - Drug Resistance …, 2021 - Elsevier
Pancreatic cancer is an aggressive malignancy with increasing incidence and poor
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …
[HTML][HTML] Cyclin dependent kinase-1 (CDK-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC)
R Wijnen, C Pecoraro, D Carbone, H Fiuji, A Avan… - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal
cancers in humans, due to late diagnosis and limited treatment possibilities. Improved …
cancers in humans, due to late diagnosis and limited treatment possibilities. Improved …
[HTML][HTML] Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance
M Capula, M Perán, G Xu, V Donati, D Yee… - Drug Resistance …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest incidence/death ratios
among all neoplasms due to its late diagnosis and dominant chemoresistance. Most PDAC …
among all neoplasms due to its late diagnosis and dominant chemoresistance. Most PDAC …
The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: interplay with the complex tumor microenvironment and novel therapeutic strategies
B El Hassouni, C Granchi, A Vallés-Martí… - Seminars in cancer …, 2020 - Elsevier
Cancer metastasis to distant organs is initiated by tumor cells that disseminate from primary
heterogeneous tumors. The subsequent growth and survival of tumor metastases depend on …
heterogeneous tumors. The subsequent growth and survival of tumor metastases depend on …
[HTML][HTML] Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
E Giovannetti, CL Van Der Borden, AE Frampton… - Seminars in cancer …, 2017 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive neoplasm, predicted
to become the second leading cause of cancer-related deaths before 2030. This dismal …
to become the second leading cause of cancer-related deaths before 2030. This dismal …
[HTML][HTML] A new oxadiazole-based topsentin derivative modulates cyclin-dependent kinase 1 expression and exerts cytotoxic effects on pancreatic cancer cells
C Pecoraro, B Parrino, S Cascioferro, A Puerta, A Avan… - Molecules, 2021 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal form of cancer characterized by
drug resistance, urging new therapeutic strategies. In recent years, protein kinases have …
drug resistance, urging new therapeutic strategies. In recent years, protein kinases have …
[HTML][HTML] Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma
M Vahabi, B Dehni, I Antomás, E Giovannetti… - Cancer and Metastasis …, 2023 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with poor
prognosis due to early metastasis, low diagnostic rates at early stages, and resistance to …
prognosis due to early metastasis, low diagnostic rates at early stages, and resistance to …